FIELD: pharmaceuticals; medicine.
SUBSTANCE: group of inventions relates to the use of mavoglurant, an mGluR5 antagonist. The following is disclosed: the use of mavoglurant to reduce cocaine intake in a patient with a cocaine intake disorder, as well as to promote abstinence from cocaine intake in a patient with a cocaine intake disorder.
EFFECT: use of the group of inventions makes it possible to effectively reduce cocaine intake and stimulate abstinence from cocaine intake in a patient with a cocaine intake disorder.
14 cl, 4 dwg, 2 ex
